CliffBio
biologic

Privigen

Immune Globulin Intravenous (Human), 10% Liquid

Loss of exclusivityFebruary 2025projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand namePrivigen
Active ingredientImmune Globulin Intravenous (Human), 10% Liquid
Strength40G
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2013
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Privigen patent cliff — loss of exclusivity February 2025 | CliffBio